Cargando…
PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428929/ http://dx.doi.org/10.1097/01.HS9.0000975912.59317.8d |
| _version_ | 1785090588393078784 |
|---|---|
| author | Linton, Kim Forconi, Francesco Lewis, David Riches, John El-Sharkawi, Dima Gleeson, Mary Injac, Sarah G Nandakumar, Srinand Tan, May Cherala, Ganesh Collins, Graham P |
| author_facet | Linton, Kim Forconi, Francesco Lewis, David Riches, John El-Sharkawi, Dima Gleeson, Mary Injac, Sarah G Nandakumar, Srinand Tan, May Cherala, Ganesh Collins, Graham P |
| author_sort | Linton, Kim |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428929 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104289292023-08-17 PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES Linton, Kim Forconi, Francesco Lewis, David Riches, John El-Sharkawi, Dima Gleeson, Mary Injac, Sarah G Nandakumar, Srinand Tan, May Cherala, Ganesh Collins, Graham P Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428929/ http://dx.doi.org/10.1097/01.HS9.0000975912.59317.8d Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Linton, Kim Forconi, Francesco Lewis, David Riches, John El-Sharkawi, Dima Gleeson, Mary Injac, Sarah G Nandakumar, Srinand Tan, May Cherala, Ganesh Collins, Graham P PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES |
| title | PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES |
| title_full | PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES |
| title_fullStr | PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES |
| title_full_unstemmed | PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES |
| title_short | PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES |
| title_sort | pb2296: robust bruton’s tyrosine kinase (btk) degradation with nx-5948, an oral btk degrader, in a first-in-human phase 1a trial in patients (pts) with relapsed/refractory b cell malignancies |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428929/ http://dx.doi.org/10.1097/01.HS9.0000975912.59317.8d |
| work_keys_str_mv | AT lintonkim pb2296robustbrutonstyrosinekinasebtkdegradationwithnx5948anoralbtkdegraderinafirstinhumanphase1atrialinpatientsptswithrelapsedrefractorybcellmalignancies AT forconifrancesco pb2296robustbrutonstyrosinekinasebtkdegradationwithnx5948anoralbtkdegraderinafirstinhumanphase1atrialinpatientsptswithrelapsedrefractorybcellmalignancies AT lewisdavid pb2296robustbrutonstyrosinekinasebtkdegradationwithnx5948anoralbtkdegraderinafirstinhumanphase1atrialinpatientsptswithrelapsedrefractorybcellmalignancies AT richesjohn pb2296robustbrutonstyrosinekinasebtkdegradationwithnx5948anoralbtkdegraderinafirstinhumanphase1atrialinpatientsptswithrelapsedrefractorybcellmalignancies AT elsharkawidima pb2296robustbrutonstyrosinekinasebtkdegradationwithnx5948anoralbtkdegraderinafirstinhumanphase1atrialinpatientsptswithrelapsedrefractorybcellmalignancies AT gleesonmary pb2296robustbrutonstyrosinekinasebtkdegradationwithnx5948anoralbtkdegraderinafirstinhumanphase1atrialinpatientsptswithrelapsedrefractorybcellmalignancies AT injacsarahg pb2296robustbrutonstyrosinekinasebtkdegradationwithnx5948anoralbtkdegraderinafirstinhumanphase1atrialinpatientsptswithrelapsedrefractorybcellmalignancies AT nandakumarsrinand pb2296robustbrutonstyrosinekinasebtkdegradationwithnx5948anoralbtkdegraderinafirstinhumanphase1atrialinpatientsptswithrelapsedrefractorybcellmalignancies AT tanmay pb2296robustbrutonstyrosinekinasebtkdegradationwithnx5948anoralbtkdegraderinafirstinhumanphase1atrialinpatientsptswithrelapsedrefractorybcellmalignancies AT cheralaganesh pb2296robustbrutonstyrosinekinasebtkdegradationwithnx5948anoralbtkdegraderinafirstinhumanphase1atrialinpatientsptswithrelapsedrefractorybcellmalignancies AT collinsgrahamp pb2296robustbrutonstyrosinekinasebtkdegradationwithnx5948anoralbtkdegraderinafirstinhumanphase1atrialinpatientsptswithrelapsedrefractorybcellmalignancies |